Donate to critical research

Help Keep Our Innovation Fund Alive

Double your impact – Give by 30 September


The Innovation Fund provides researchers with the opportunity to conduct ground-breaking research in areas that have not been studied before.

It is an important early step in the process to develop new clinical trials.

We need urgent help to ensure critical early stage research can continue.

The recent coronavirus crisis has had a devastating impact on our fundraising ability for one of the most important initiatives we support – the Innovation Fund.

The Innovation Fund, which is granted annually, allows researchers to receive much-needed financial assistance to kick start a new idea that can give us critical insights into GI cancer treatment. It’s where breakthroughs in GI cancer research are born.

And it’s at grave risk right now, unless we can raise $200,000 to keep it going!

Thanks to an extremely generous supporter, every dollar we can raise by 30 September 2020 will be matched.

Please help us continue our search for new treatments and provide hope for those diagnosed with GI cancer by giving an urgent gift today – you’ll be able to double your impact on the clinical trials that save lives.

Sadly, there is a direct correlation between how much money a disease receives for research, and how many lives are saved. The fact is, around four out of five research projects never get off the ground, because competition for grants is so fierce – and the pool of funding so small.

We need caring, compassionate people like you to support our work.

Here’s the dilemma: without any data, you cannot apply for a government or industry supported grant. But without money, you can’t gather any data.

That’s where our Innovation Fund comes in. This Fund is designed to help researchers with big ideas germinate those projects, and bring them to a point at which they can become eligible for larger funding grants – initiating the clinical trials that give people with GI cancer better outcomes and real hope.

The past recipients of the Innovation Fund grant all agree that it gave hope to their patients by enabling them to conduct new research that would not be possible otherwise. See below for  insights in to some of the research undertaken to date.

“I am thrilled that we have received the Innovation Fund grant to conduct the pilot study ‘An organoid sensitivity testing driven umbrella study for patients with refractory metastatic colorectal cancer’. This grant will enable us to test a new development in personalised bowel cancer treatment that could give hope to people who have no other options,” – Prof. Peter Gibbs: 2019 Innovation Fund grant recipient
“Neuropathy is a side effect from Oxaliplatin, a chemotherapy used to treat advanced colorectal cancer. Patients experience pain in their hands and feet. This study will investigate if the tablet ibudilast could prevent and treat neurotoxicity, meaning that patients will not suffer from as much neuropathy. It could enable them to have more chemotherapy and improve their survival and quality of life,” –Prof. Janette Vardy: 2018 Innovation Fund grant recipient
  “The 2017 Innovation Fund grant will support the RENO study (REctal cancer No Operation). This study will examine whether some people being treated for rectal cancer can forgo surgery after chemoradiotherapy treatment. We are thrilled to receive this funding that will hopefully reduce the need for surgery that can have long-term side effects for many patients.” -Prof. Chris Karapetis: 2017 Innovation Fund grant recipient
    “The Innovation Fund grant provided necessary funds to begin the pre-planned and very exciting DOCTOR genomic sub study. The grant funded DNA copy number analyses that was performed on tumour tissues from participants providing important insights in oesophageal tumour biology.” –Prof. Andrew Barbour: 2015 Innovation Fund grant recipient

Although our team adventures can no longer take place, you can still take on a personal Gutsy Challenge to support the Innovation Fund.

Find out more